Zymergen Inc. (ZY): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZY Stock Price Chart Interactive Chart >
ZY Price/Volume Stats
Current price | $1.27 | 52-week high | $46.05 |
Prev. close | $1.32 | 52-week low | $1.20 |
Day low | $1.20 | Volume | 1,137,600 |
Day high | $1.36 | Avg. volume | 1,061,415 |
50-day MA | $2.27 | Dividend yield | N/A |
200-day MA | $7.16 | Market Cap | 130.99M |
Zymergen Inc. (ZY) Company Bio
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
Latest ZY News From Around the Web
Below are the latest news stories about Zymergen Inc that investors may wish to consider to help them evaluate ZY as an investment opportunity.
What You Need To Know About Zymergen Inc.'s (NASDAQ:ZY) Investor CompositionA look at the shareholders of Zymergen Inc. ( NASDAQ:ZY ) can tell us which group is most powerful. Insiders often own... |
Zymergen (ZY) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceThe following slide deck was published by Zymergen Inc. in conjunction with this event.... |
Zymergen debuts Automation business and shares program portfolioZymergen (ZY) announces a new Automation business and updated portfolio |
Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare ConferenceDelivering platform expertise and developing novel microbes, molecules and materials for customers across a variety of marketsSAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen (ZY) today announced a new Automation business and updated portfolio, further refining the company’s focus on high-value solutions where its proprietary platform can provide distinct advantages. Zymergen’s Automation business delivers proven automation technology to organizations interested in |
Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World’s Largest Metagenomics Databases and Proprietary Synthetic Biology PlatformExploring natural products for innovative therapeuticsSAN FRANCISCO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen (ZY) announced a new drug discovery business based around their proprietary synthetic biology platform and what is believed to be the world’s largest metagenomics database, combining both size and quality. This new business leverages Zymergen’s differentiated access to natural products as a source of diverse chemical matter and augments Zymergen’s existing advance |
ZY Price Returns
1-mo | -29.44% |
3-mo | -67.68% |
6-mo | -86.33% |
1-year | -96.38% |
3-year | N/A |
5-year | N/A |
YTD | -81.02% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...